FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2913223764> ?p ?o ?g. }

• W2913223764 endingPage "103" @default.
• W2913223764 startingPage "103" @default.
• W2913223764 abstract "Abstract Background Intensive efforts of genome sequencing studies during the past decade identified >100 driver genes recurrently mutated in one or more subtypes of myeloid neoplasms, which collectively account for the pathogenesis of >90% of the cases. However, approximately 10% of the cases have no alterations in known drivers and their pathogenesis is still unclear. A possible explanation might be the presence of alterations in non-coding regions that are not detected by conventional exome/panel sequencing; mutations and complex structural variations (SVs) affecting these regions have been shown to deregulate expression of relevant genes in a variety of solid cancers. Unfortunately, however, no large studies have ever been performed, in which a large cohort of myeloid malignancies were analyzed using whole genome sequencing (WGS) in an attempt to identify a full spectrum of non-coding alterations, even though its efficacy have been demonstrated in many solid cancers. In this study, we performed WGS in a large cohort of pan-myeloid cancers, in which both coding and non-coding lesions were comprehensively analyzed. Patients and methods A total of 338 cases of myeloid malignancies, including 212 with MDS, 70 with AML, 17 with MDS/MPN, 23 with t-AML/MDS, and 16 with MPN were analyzed with WGS, of which 173 were also analyzed by transcriptome sequencing. Tumor samples were obtained from patients' bone marrow (N=269) or peripheral blood (N=69), while normal controls were derived from buccal smear (N=263) or peripheral T cells (N=75). Sequencing of target panel of 86 genes were performed for all samples. Sequencing data were processed using in-house pipelines, which were optimized for detection of complex structural variations (SVs) and abnormalities in non-coding sequences. Results WGS identified a median of 586,612 single nucleotide variants (SNVs) and 124,863 short indels per genome. NMF-based decomposition of the variants disclosed three major mutational signatures, which were characterized by age-related C>T transitions at CpG sites (Sig. A), C>T transitions at CpT sites (Sig. B), and T>C transitions at ApTpN context (Sig. C). Among these, Sig. C showed a prominent strand bias and corresponds to COSMIC signature 16, which has recently been implicated in alcohol drinking. Significant clustering of SNVs and short indels were interrogated across the genome divided into different window sizes (1Kbp, 10Kbp, 100Kbp) or confining the targets to coding exons and known regulatory regions, such as promoters, enhancers/super enhances, and DNase I hypersensitive sites. Recapitulating previous findings, SNVs in the coding exons were significantly enriched in known drivers, including TP53, TET2, ASXL1, DNMT3A, SF3B1, RUNX1, EZH2, and STAG2. We detected significant enrichment of SNVs in CpG islands, and promoters/enhancers. We also detected a total of 8,242 SVs with a median of 15 SVs/sample, which is more prevalent than expected from conventional karyotype analysis. Focal clusters of complex rearrangements compatible with chromothripsis were found in 8 cases, of which 7 carried biallelic TP53 alterations. NMF-based signature analysis of SVs revealed that large (>1Mb) deletions, inversions, and tandem duplications and translocations are clustered together and were strongly associated with TP53 mutations, while smaller deletions and tandem duplications, but not inversions, constitute another cluster. As expected, FLT3-ITD (N=15) and MLL-PTD (N=12) were among the most frequent SVs. Unexpectedly, in addition to known SVs associated with t(8;21) (RUNX1-RUNX1T1) (N=6) and t(3;21) (RUNX1-MECOM) (n=1) as well as non-synonymous SNVs within the coding exons (N=30), we detected frequent non-coding alterations affecting RUNX1, including SVs (N=15) and SNVs around splicing acceptor sites (N=5), suggesting that RUNX1 was affected by multiple mechanism, where as many as 38% of RUNX1 lesions were explained by non-coding alterations. Other recurrent targets of non-coding lesions included ASXL1, NF1, and ETV6. Conclusions WGS was successfully used to reveal a comprehensive registry of genetic alterations in pan-myeloid cancers. Non-coding alterations affecting known driver genes were more common than expected, suggesting the importance of detecting non-coding abnormalities in diagnostic sequencing. Disclosures Nakagawa: Sumitomo Dainippon Pharma Co., Ltd.: Research Funding. Usuki:Mochida Pharmaceutical: Speakers Bureau; Astellas Pharma Inc.: Research Funding; Sanofi K.K.: Research Funding; GlaxoSmithKline K.K.: Research Funding; Otsuka Pharmaceutical Co., Ltd.: Research Funding; Kyowa Hakko Kirin Co., Ltd.: Research Funding; Daiichi Sankyo: Research Funding; Celgene Corporation: Research Funding, Speakers Bureau; SymBio Pharmaceuticals Limited.: Research Funding; Shire Japan: Research Funding; Janssen Pharmaceutical K.K: Research Funding; Boehringer-Ingelheim Japan: Research Funding; Sumitomo Dainippon Pharma: Research Funding, Speakers Bureau; Pfizer Japan: Research Funding, Speakers Bureau; Novartis: Speakers Bureau; Nippon Shinyaku: Speakers Bureau; Chugai Pharmaceutical: Speakers Bureau; Takeda Pharmaceutical: Speakers Bureau; Ono Pharmaceutical: Speakers Bureau; MSD K.K.: Speakers Bureau. Chiba:Bristol Myers Squibb, Astellas Pharma, Kyowa Hakko Kirin: Research Funding. Miyawaki:Otsuka Pharmaceutical Co., Ltd.: Consultancy; Novartis Pharma KK: Consultancy; Astellas Pharma Inc.: Consultancy." @default.
• W2913223764 created "2019-02-21" @default.
• W2913223764 creator A5000473933 @default.
• W2913223764 creator A5009065536 @default.
• W2913223764 creator A5017171769 @default.
• W2913223764 creator A5018101881 @default.
• W2913223764 creator A5020940867 @default.
• W2913223764 creator A5021004681 @default.
• W2913223764 creator A5030791716 @default.
• W2913223764 creator A5031014013 @default.
• W2913223764 creator A5036465231 @default.
• W2913223764 creator A5042588749 @default.
• W2913223764 creator A5046825627 @default.
• W2913223764 creator A5050011235 @default.
• W2913223764 creator A5050620740 @default.
• W2913223764 creator A5050909216 @default.
• W2913223764 creator A5057095764 @default.
• W2913223764 creator A5062668386 @default.
• W2913223764 creator A5063094149 @default.
• W2913223764 creator A5065025175 @default.
• W2913223764 creator A5066055908 @default.
• W2913223764 creator A5067804516 @default.
• W2913223764 creator A5069614210 @default.
• W2913223764 creator A5070075379 @default.
• W2913223764 creator A5070702322 @default.
• W2913223764 creator A5072513476 @default.
• W2913223764 creator A5076753985 @default.
• W2913223764 creator A5082893222 @default.
• W2913223764 creator A5086317159 @default.
• W2913223764 creator A5088167618 @default.
• W2913223764 creator A5089636566 @default.
• W2913223764 date "2018-11-29" @default.
• W2913223764 modified "2023-10-18" @default.
• W2913223764 title "Genome-Wide Analysis of Non-Coding Alterations in Pan-Myeloid Cancers Using Whole Genome Sequencing" @default.
• W2913223764 doi "https://doi.org/10.1182/blood-2018-99-116250" @default.
• W2913223764 hasPublicationYear "2018" @default.
• W2913223764 type Work @default.
• W2913223764 sameAs 2913223764 @default.
• W2913223764 citedByCount "0" @default.
• W2913223764 crossrefType "journal-article" @default.
• W2913223764 hasAuthorship W2913223764A5000473933 @default.
• W2913223764 hasAuthorship W2913223764A5009065536 @default.
• W2913223764 hasAuthorship W2913223764A5017171769 @default.
• W2913223764 hasAuthorship W2913223764A5018101881 @default.
• W2913223764 hasAuthorship W2913223764A5020940867 @default.
• W2913223764 hasAuthorship W2913223764A5021004681 @default.
• W2913223764 hasAuthorship W2913223764A5030791716 @default.
• W2913223764 hasAuthorship W2913223764A5031014013 @default.
• W2913223764 hasAuthorship W2913223764A5036465231 @default.
• W2913223764 hasAuthorship W2913223764A5042588749 @default.
• W2913223764 hasAuthorship W2913223764A5046825627 @default.
• W2913223764 hasAuthorship W2913223764A5050011235 @default.
• W2913223764 hasAuthorship W2913223764A5050620740 @default.
• W2913223764 hasAuthorship W2913223764A5050909216 @default.
• W2913223764 hasAuthorship W2913223764A5057095764 @default.
• W2913223764 hasAuthorship W2913223764A5062668386 @default.
• W2913223764 hasAuthorship W2913223764A5063094149 @default.
• W2913223764 hasAuthorship W2913223764A5065025175 @default.
• W2913223764 hasAuthorship W2913223764A5066055908 @default.
• W2913223764 hasAuthorship W2913223764A5067804516 @default.
• W2913223764 hasAuthorship W2913223764A5069614210 @default.
• W2913223764 hasAuthorship W2913223764A5070075379 @default.
• W2913223764 hasAuthorship W2913223764A5070702322 @default.
• W2913223764 hasAuthorship W2913223764A5072513476 @default.
• W2913223764 hasAuthorship W2913223764A5076753985 @default.
• W2913223764 hasAuthorship W2913223764A5082893222 @default.
• W2913223764 hasAuthorship W2913223764A5086317159 @default.
• W2913223764 hasAuthorship W2913223764A5088167618 @default.
• W2913223764 hasAuthorship W2913223764A5089636566 @default.
• W2913223764 hasBestOaLocation W29132237641 @default.
• W2913223764 hasConcept C104317684 @default.
• W2913223764 hasConcept C10590036 @default.
• W2913223764 hasConcept C132917006 @default.
• W2913223764 hasConcept C141231307 @default.
• W2913223764 hasConcept C150194340 @default.
• W2913223764 hasConcept C162317418 @default.
• W2913223764 hasConcept C16671776 @default.
• W2913223764 hasConcept C24432333 @default.
• W2913223764 hasConcept C2778729363 @default.
• W2913223764 hasConcept C2779282312 @default.
• W2913223764 hasConcept C501734568 @default.
• W2913223764 hasConcept C502942594 @default.
• W2913223764 hasConcept C51679486 @default.
• W2913223764 hasConcept C54355233 @default.
• W2913223764 hasConcept C70721500 @default.
• W2913223764 hasConcept C86803240 @default.
• W2913223764 hasConceptScore W2913223764C104317684 @default.
• W2913223764 hasConceptScore W2913223764C10590036 @default.
• W2913223764 hasConceptScore W2913223764C132917006 @default.
• W2913223764 hasConceptScore W2913223764C141231307 @default.
• W2913223764 hasConceptScore W2913223764C150194340 @default.
• W2913223764 hasConceptScore W2913223764C162317418 @default.
• W2913223764 hasConceptScore W2913223764C16671776 @default.
• W2913223764 hasConceptScore W2913223764C24432333 @default.
• W2913223764 hasConceptScore W2913223764C2778729363 @default.
• W2913223764 hasConceptScore W2913223764C2779282312 @default.
• W2913223764 hasConceptScore W2913223764C501734568 @default.
• W2913223764 hasConceptScore W2913223764C502942594 @default.

• next